MAML2 and neoplasm: Indeed, a prognostic classification recently proposed in the first-line setting of advanced PSCC receiving cisplatin-based chemotherapy included one clinical factor, visceral disease, and one tumor tissue molecular factor, MAML2 gene expression (Necchi et al., 2016a).